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institutionalized, U.S. civilian population were analyzed.
MEPS data provided information on demographics,
health conditions, prescription medications, and health
resource utilization. Persons >= 45 years with COPD
(ICD-9 = 491 [chronic bronchitis], ICD-9 = 492 [emphy-
sema]) as their primary diagnosis were included. Direct
medical costs were deﬁned as the sum of insurance and
patient payments for health services attributable to
COPD. This included emergency department visits, 
hospital outpatient visits, inpatient stays, outpatient 
clinic and ofﬁce visits, and prescription medications.
Descriptive statistics were conducted. Results were
weighted to reﬂect population estimates.
RESULTS: In 1996, 1.4 million people over 45 years of
age received medical treatment for COPD. 65.7% of this
cohort were 65 and older. Direct medical costs attribut-
able to COPD totaled $3.4 billion. COPD-associated
direct medical costs for persons 65 and older were $3.1
billion. 77% of the total medical costs in this group of
patients were due to hospital admissions, 14.3% were for
prescription medications, and 5.5% were for emergency
room and hospital outpatient visits.
CONCLUSIONS: Inpatient admissions in the elderly
accounted for the majority of the COPD-associated costs.
Interventions designed to manage COPD more effectively,
including appropriate utilization of prescription medica-
tions, may help minimize ER visits and hospital admis-
sions, thereby decreasing total costs of managing COPD.
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OBJECTIVES: Outcomes in asthmatic patients may vary
depending on the controller medication used. Observa-
tional studies of outcomes of asthma therapy are needed
to understand the implications of choice of controller 
in different populations. This study compared asthma-
related health care costs and medication compliance
between patients newly started on montelukast compared
to low-dose ﬂuticasone propionate as controller therapy
in Medicaid-enrolled asthmatic patients previously using
only short-acting beta-agonists.
METHODS: Using data from the North Carolina 
Medicaid program, we identiﬁed continuously enrolled
asthmatic patients starting either ﬂuticasone propionate
44mg (FP 44), an inhaled corticosteroid, (n = 353) or
montelukast 5 and 10mg, an oral leukotriene modiﬁer, (n
= 525) in the year 1998. Patients were followed for 1-
year pre and post controller initiation for health care
service utilization, medication reﬁll patterns, and costs. A
mixed modeling procedure with indicator variables to
adjust for potential confounders was used to determine
the adjusted cost impact of therapy initiation.
RESULTS: The average asthma-related health care costs
were $1199 ($1180 for FP, $1212 for montelukast) in
Year 1. These costs increased to $1342 ($1235 for FP,
$1415 for montelukast) in Year 2. There were no signif-
icant differences in the adjusted asthma-related health
care costs. In both groups, physician visits were signiﬁ-
cantly higher in Year 2 (50% increase for FP, 23% for
montelukast, both p < 0.01). However, even after allow-
ing for a wider compliance range for FP (50–150%) com-
pared to montelukast (80–120%), we found montelukast
users to be more compliant with therapy in Year 2 (RR:
1.97; 95% CI: 1.25, 3.13).
CONCLUSIONS: Although there were no cost or 
health care utilization differences between the two groups
in the post-controller initiation year, montelukast use was
associated with signiﬁcantly better treatment compliance
than FP use, which could have signiﬁcant implications 
for long-term patient outcomes and costs in 
Medicaid-enrolled asthmatic patients.
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OBJECTIVES: Asthma controller therapy with multiple
controller medications is increasingly common. Data is
needed regarding the implications of the choice for a
second controller medication. The goal of this study 
was to compare asthma-related health care costs and
medication compliance between patients newly started on
montelukast compared to salmeterol as additional 
controller therapy among patients already using inhaled
corticosteroids (ICS).
METHODS: Using data from the North Carolina 
Medicaid program, we identiﬁed continuously enrolled
asthmatic patients using ICS as controller therapy (≥4
reﬁlls in year before starting additional controller) initi-
ating either salmeterol a long-acting beta agonist, (n = 97)
or montelukast, an oral leukotriene modiﬁer, (n = 101) in
the year 1998. Each group was observed for 1-year pre
and post additional controller medication initiation for
health care service utilization, medication reﬁll patterns,
and costs. A mixed modeling procedure using indicator
variables was used to determine confounder controlled
cost impact of therapy initiation.
RESULTS: The average asthma-related health care costs
were $1955 ($2225 for salmeterol, $1695 for mon-
telukast) in year 1. These average costs did not signiﬁ-
cantly increase for either group ($2055 entire population,
